Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(10):1484-1498.
doi: 10.2174/1570159X16666180110130253.

Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities

Amalia Merelli  1   2 , Julio César García Rodríguez  3 , Jaume Folch  4   5 , Marcelo R Regueiro  6 , Antoni Camins  5   7   8 , Alberto Lazarowski  1   2
Affiliations
Review

Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities

Amalia Merelli et al. Curr Neuropharmacol. 2018.

Abstract

Neurodegeneration (NDG) is linked with the progressive loss of neural function with intellectual and/or motor impairment. Several diseases affecting older individuals, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington's disease, Parkinson's disease, stroke, Multiple Sclerosis and many others, are the most relevant disorders associated with NDG. Since other pathologies such as refractory epilepsy, brain infections, or hereditary diseases such as "neurodegeneration with brain iron accumulation", also lead to chronic brain inflammation with loss of neural cells, NDG can be said to affect all ages. Owing to an energy and/or oxygen supply imbalance, different signaling mechanisms including MAPK/PI3K-Akt signaling pathways, glutamatergic synapse formation, and/or translocation of phosphatidylserine, might activate some central executing mechanism common to all these pathologies and also related to oxidative stress. Hypoxia inducible factor 1-α (HIF-1α) plays a twofold role through gene activation, in the sense that this factor has to "choose" whether to protect or to kill the affected cells. Most of the afore-mentioned processes follow a protracted course and are accompanied by progressive iron accumulation in the brain. We hypothesize that the neuroprotective effects of iron chelators are acting against the generation of free radicals derived from iron, and also induce sufficient -but not excessive- activation of HIF-1α, so that only the hypoxia-rescue genes will be activated. In this regard, the expression of the erythropoietin receptor in hypoxic/inflammatory neurons could be the cellular "sign" to act upon by the nasal administration of pharmacological doses of Neuro-EPO, inducing not only neuroprotection, but eventually, neurorepair as well.

Keywords: HIF-1; MDR-1; Neuro-EPO; Neurodegeneration; neuroprotection; refractory epilepsy..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Neurodegenerative diseases treated with M-30, DFO or Mimosine that increase HIF-1 activation with neuroprotective effects.
Fig. (2)
Fig. (2)
HIF-1 dependent progressive neurodegenerative process could be avoided if EPO is nasally administered.
See this image and copyright information in PMC

References

    1. Toledano I. AL. Hacia el equilibrio de la población mundial (Cátedra de Bioética) Book. 2004 Publisher: Desclée De Brouwer, Edition: Softcover, Language: Spanish 440 pages. ISBN13. 2004.
    1. WHO World report on ageing and health. www.who.int/ageing/ publications/world-report-2015
    1. Piret J.P., Mottet D., Raes M., Michiels C. Is HIF-1〈 a pro- or an anti-apoptotic protein? Biochem. Pharmacol. 2002;64(5-6):889–892. [http://dx.doi.org/10.1016/S0006-2952(02)01155-3]. [PMID: 12213583]. - PubMed
    1. Sanchez P.E., Fares R.P., Risso J.J., Bonnet C., Bouvard S., Le-Cavorsin M., Georges B., Moulin C., Belmeguenai A., Bodennec J., Morales A., Pequignot J.M., Baulieu E.E., Levine R.A., Bezin L. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc. Natl. Acad. Sci. USA. 2009;106(24):9848–9853. [http://dx.doi.org/10.1073/pnas. 0901840106]. [PMID: 19497871]. - PMC - PubMed
    1. Rodríguez C., García F.A., Amaro G.D., García R.J.C. Neuroprotección en enfermedades Neuro y Heredo degenerativas; García Rodríguez, J.C., Ed.; OmniaScience: Barcelona, España, 2014. De la Neuroprotección a la Neurorestauración. Evidencias de las Potencialidades de la Neuro-eritropoyetina (Neuro-EPO). .

MeSH terms